Akorn Recalls Acetylcysteine for Injection Due to Manufacturing Deviations
Akorn, Inc. is recalling 89,507 vials of Acetylcysteine for Injection due to Current Good Manufacturing Practice (CGMP) deviations. The recall is classified as FDA Class II.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, which indicates a reasonable probability of temporary or medically reversible adverse health consequences. The source text does not report any specific illnesses, injuries, or fatalities, placing this in the 'High' severity category per the rubric for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Akorn, Inc. is voluntarily recalling 89,507 vials of Acetylcysteine for Injection 6 g/30 mL (200 mg/mL), NDC 17478-660-30. The recall was initiated on June 22, 2018, and was classified as FDA Class II on July 9, 2018. The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations.
The affected lots are 061496A (Exp. 06/2018), 111696A (Exp. 11/2018), 061947A (Exp. 06/2019), and 091267A (Exp. 09/2019). The product was distributed nationwide in the United States. The recall status is currently Terminated, with a termination date of November 6, 2020.
Healthcare providers and patients should check their inventory for these specific lot numbers and expiration dates. If you have this product, contact your healthcare provider or pharmacist for instructions on how to dispose of or return the medication. Do not use the recalled product.
The recalled product
- Product
- Acetylcysteine for Injection 6 g/30 mL (200 mg/mL). Rx Only. Manufactured by Akron Inc., Lake Forest, IL 60045. NDC 17478-660-30.
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Injectable Medication
- Hazard
- Affected units
- 89,507
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lots: 061496A
- Exp. 06/2018
- 111696A
- Exp. 11/2018
- 061947A
- Exp. 06/2019
- 091267A
- Exp. 09/2019
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviations
See all →- ModerateFentanyl Citrate Injectable Solution Recall Due to cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateDrug Recall: APAP 500 mg Phenyl HCl Tablets for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateMigrenol Caplet Drug Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16